UPitt researchers found that using an FDA-cleared procalcitonin assay did not significantly change the use of antibiotics for patients suspected of having lower respiratory tract infections.
In 2018, the company expects to place between 140 and 170 new ePlex analyzers, and an annuity per ePlex in the $100,000 to $120,000 range.
The company's Diagnostics business was up 14 percent, while its Life Sciences business grew 13 percent. The firm also closed its $2 billion buy of IDT last week.
Using an immunoassay as an initial screening tool saved approximately $36,000 over multiplex PCR panel use alone when performed in a period of high flu prevalence.
Guidance for 2018 placements of ePlex respiratory testing systems is lower than analysts’ estimates, but the firm communicated remedies for adoption challenges.
On a conference call following the release of the earnings, the firm's CEO guided for lower 2018 ePlex placements than had been expected by analysts.
Qiagen believes the flexibility of the Stat-Dx platform for an evolving reimbursement landscape will set it apart from other similar commercial platforms.
The firm is developing a rapid point-of-care diagnostic system focused on combating antimicrobial resistance.
At the JPM Healthcare Conference on Wednesday, its CEO also said that lower-than-anticipated revenues in Q4 2017 were due to a longer-than-expected sales cycle.
The team hopes to commercialize the technology by producing cost-effective tests to rapidly diagnose common upper respiratory viral pathogens.